MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1111/ene.15113

Медицинская библиотека · European journal of neurology · 2021

Declining mortality of cerebral venous sinus thrombosis with thrombocytopenia after SARS-CoV-2 vaccination.

van de Munckhof Anita, Krzywicka Katarzyna, Aguiar de Sousa Diana, Sánchez van Kammen Mayte, Heldner Mirjam R, Jood Katarina, Lindgren Erik, Tatlisumak Turgut, Putaala Jukka, Kremer Hovinga Johanna A, Middeldorp Saskia, Levi Marcel, Arnold Marcel, Ferro José M, Coutinho Jonathan M

СтатьяПеревод в очереди

Аннотация

BACKGROUND AND PURPOSE: High mortality rates have been reported in patients with cerebral venous sinus thrombosis (CVST) due to vaccine-induced immune thrombotic thrombocytopenia (VITT) after vaccination with adenoviral vector SARS-CoV-2 vaccines. The aim of this study was to evaluate whether the mortality of patients with CVST-VITT has decreased over time.

METHODS

The EudraVigilance database of the European Medicines Agency was used to identify cases of CVST with concomitant thrombocytopenia occurring within 28 days of SARS-CoV-2 vaccination. Vaccines were grouped based on vaccine type (adenoviral or mRNA). Cases with CVST onset until 28 March were compared to cases after 28 March 2021, which was the day when the first scientific paper on VITT was published.

RESULTS

In total, 270 cases of CVST with thrombocytopenia were identified, of which 266 (99%) occurred after adenoviral vector SARS-CoV-2 vaccination (ChAdOx1 nCoV-19, n = 243; Ad26.COV2.S, n = 23). The reported mortality amongst adenoviral cases with onset up to 28 March 2021 was 47/99 (47%, 95% confidence interval 37%-58%) compared to 36/167 (22%, 95% confidence interval 16%-29%) in cases with onset after 28 March (p < 0.001). None of the four cases of CVST with thrombocytopenia occurring after mRNA vaccination died.

CONCLUSION

The reported mortality of CVST with thrombocytopenia after vaccination with adenoviral vector-based SARS-CoV-2 vaccines has significantly decreased over time, which may indicate a beneficial effect of earlier recognition and/or improved treatment on outcome after VITT.

Для цитирования: van de Munckhof Anita, Krzywicka Katarzyna, Aguiar de Sousa Diana, Sánchez van Kammen Mayte, Heldner Mirjam R, Jood Katarina, Lindgren Erik, Tatlisumak Turgut, Putaala Jukka, Kremer Hovinga Johanna A, Middeldorp Saskia, Levi Marcel, Arnold Marcel, Ferro José M, Coutinho Jonathan M. Declining mortality of cerebral venous sinus thrombosis with thrombocytopenia after SARS-CoV-2 vaccination.. European journal of neurology. 2021. DOI: 10.1111/ene.15113.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.